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Surface Dosimetry in Breast Radiotherapy
Andrew Kelly
A Thesis for Masters
Centre for Medical Radiation Physics, Engineering Physics
University of Wollongong

ABSTRACT

Radiotherapy is a common tool used by clinicians in the treatment of breast cancer
patients. This thesis investigates the calculation and measurement of phantom surface
dose during an IMRT breast radiation therapy dose delivery.
Measurements were taken to prototype the MOSkin dosimeters placed on an anthropomorhic phantom. The dose measurements are also indicative of skin doses that
patients are likely to receive with and without Orfit immobilisation cast material in
place during radiation therapy.
The first part of this thesis is focussed on the beam modelling of the Pinnacle
planning computer. In particular, it focusses on the ability of the planning system
to accurately model a medical linear accelerator and calculate dose distributions in
the build-up region. The reason this is relevant is because to date, planning system
calculations are innaccurate in the build-up region, and calculated doses are thus
discarded pieces of information. It was found that build-up dose calculations using
a treatment planning system (TPS) could be improved by using Monte Carlo (MC)
data as input to the beam modelling algorithm. These calculations were performed in
cuboid phantom geometry as a precursor to curved contours.
The last part of this thesis investigates the dosimetric impact of using an immobilisation cast in breast radiotherapy. This study involved an anthropomorphic phantom
and the use of EBT GafChromic film and MOSkins to investigate the magnitude of

dose deposition at skin depth both with, and without, the Orfit immobilisation cast
present. Dosimetric measurements were reported at numerous points of clinical interest to determine whether the Orfit immobilisation cast may be used in radiotherapy of
the breast. Results show increases in dose to the breast surface, the clinical significance
of which may be a matter for consideration by clinicians.

KEYWORDS: Breast Radiotherapy, Skin Dosimetry
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Chapter 1
Introduction
1.1

Breast Cancer Incidence and Risk Factors

Breast cancer incidence has increased over the last twenty years in Australia and
is projected to continue increasing. Data from the Australian Institute of Health
and Welfare (McDermid, 2005) illustrates that from 1982-1991 reported breast cancer
incidence increased 53% from 5244 to 8043 cases. From the period 1992-2001 an
increase of 47% is reported from 8027 cases up to 11791. Projections give the incidence
of breast cancer rising from 12081 to 14816 over the period 2002 to 2011, a 23% rise.
From this data it can be seen that the rate of increase is slowing however. This could be
attributed to greater use of screening methods such as mammography. With increased
use of mammography, it may be that a backlog of patients who would previously
have gone undetected have been accounted for and a more regular regime of screening
has shown reduced incidence with each year. Data from the Australian Institute of
Health and Welfare (AIHW, 2006) shows that in the period 1992-1997 breast cancer
accounted for 27% of cancers among women with a 5 year relative survival rate of
84%. The survival rate compares women diagnosed with breast cancer to women
of the same demographic without breast cancer. Compared to lung cancer which
1
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accounted for 6.6% of women’s cancers with a 5 year 14% relative survival rate, breast
cancer patients have a much higher survival rate.
The American Cancer Society identifies a number of risk factors contributing to
the incidnce of breast cancer. Among these are controllable and non controllable
factors. Some of the non-controllable factors include: family predisposition (genetics),
age, late menopause, and breast density. Among the factors that can be influenced
are things such as: physical inactivity, use of estrogen and progestin birth control
pills, and alcohol consumption. Regardless of the factors influencing the induction of
cancer, it is vitally important to maintain a regular breast screening regimen given the
correlation between breast cancer stage and 5 year survival rates (AIHW, 2009).

1.2

Radiotherapy and its Side Effects in Breast
Treatment

Radiotherapy is the delivery of ionising radiation to a defined area of the body containing cancer cells. The aim is to cause sufficient damage to the cancer cells DNA so that
DNA repair mechanisms can no longer salvage the cells and they die spontaneously or
through programmed cell death (apoptosis). The measure of radiation is dose, given
by the unit gray (Gy), being the energy in Joules (J) absorbed per unit kilogram (kg).
Breast radiotherapy can result in various side effects as collateral to the elimination of primary breast cancer. These effects can be both deterministic and stochastic
in response to absorption of radiation into bodily tissues. An example of each of
these effects of radiation are normal tissue damage and secondary cancer incidence
respectively. Regions of the body which may sustain damage due to breast radiotherapy are the: heart, lungs, breast, and skin. When the heart is irradiated progressive
fibrotic changes can occur throughout including pericardial, endocardial and myocar-
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dial tissues. These are late effects of radiotherapy and therefore lead to morbidity and
mortality later in life. A side effect of lung irradiation is radiation pneumonitis which
is acute inflammation of the lung causing decreased pulmonary function and possible
long term fibrotic changes. Irradiation of the skin causes erythema in the short term
and may cause desquamation. The skin may also get long lasting colour changes,
induration and telangiectasia. All these tissues may sustain damage with a normal
tissue complication probability that increases with dose. Knowledge of tolerance dose
to various tissues is outlined in Qantec (Bentzen et al., 2010). A search of this reveals that skin dose is not one of the organs characterised. The older historical paper
(Emami et al., 1991) does give skin toxicity but it is not clear from the document
whether the toxicity dose values are based on surface dose or incident dose. Secondary
cancer induction is a risk in all organs and even low doses are a risk (Hall & Wuu,
2003).

1.3
1.3.1

Project Definition
Improving Surface Dose Calculation in Treatment Planning

Calculation of doses throughout the patient is currently performed in the planning
stage of radiotherapy using computerised radiation therapy treatment planning systems (TPS). This is done in order to tailor particular radiotherapy regimens to each
patient, aiming to improve patient outcomes. Currently ion chamber data is used as
input. This data is then matched using various auto-modelling routines to best model
the beam characteristics of a particular linear accelerator. The process begins with a
photon energy spectrum and from there the effect of each component of the real linear
accelerator which affects the beam-line is mathematically modelled. Such components
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include: primary collimator, flattening filter, X and Y jaws and multileaf collimators.
Once the beam-line configuration is modelled then dose profiles and depth-dose distributions are calculated and compared to the experimentally acquired ion chamber data
that is input for verification of the beam model by comparison. This process is performed iteratively until the solution is adequate. The problem with using ion chamber
data is that at the surface, ion chamber dose measurements can be inaccurate for a
number of reasons. For example, one reason is that the inner size of the ion chamber
over which the dose is integrated is too large compared to the dose gradient in the
build-up region where electron disequilibrium exists. The beam modelling process can
also be achieved by using Monte Carlo (MC) data. Note, an appropriately commissioned MC data set does not suffer significant inaccuracy in the build-up region such
as a typical ion chamber.
MC simulation in this setting is the process of repeated random number sampling
to drive the simulation of radiation interaction and transport through matter. This is
a very powerful technique because an understanding of dose deposition can be formed
free from the limitations of real-world experimentation.

1.3.2

Measuring Surface Dose in Breast Radiotherapy

Penduous breasts present clinicians with some difficulty in providing radiotherapy
treatment. This is because they tend to have poor setup reproducibility and as a
result, the delivered dose distribution is not identical to the planned dose distribution.
This can have serious repurcussions in the form of losing tumour control or causing unacceptable side effects to normal tissues. One of the tools available to clinicians which
they can use to remedy this problem is immobilisation casts. One of the objectives of
this study is to measure the dose increase to the patient surface when a particular immobilisation cast, Orfit, is employed. Any material placed on the patient surface will
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provide a bolus effect to some degree. This thesis does not attempt to answer whether
the increase in dose is acceptable, such a question would require considerations outside
the scope of this thesis. What is hoped is that the surface dose information provided
in this thesis can be used by clinicians for consideration as to the use of breast immobilisation. A major challenge is that existing skin toxicity versus dose data is based on
incident dose at dmax of prescribed dose from combined beams at isocentre. As true
dose at skin depth can be provided by the new MOSkin dosimeters used in this study
it is hoped that they may in future be used as in-vivo dosimeters on breast patients
where skin reaction is tracked.

1.3.3

Research Questions

1. Can surface dose prediction in the build-up region be improved in Pinnacle RTP
with the use of data from a Monte Carlo simulated linear accelerator to build
the beam model?
2. What are the typical increases in skin dose in breast radiotherapy when using
an Orfit immobilisation cast?
3. What are the advantages and disadvantages of EBT film and MOSkin dosimeters
for in-vivo breast dose measurement?

Chapter 2
Background
2.1

Therapy Options For Breast Cancer Patients

Over the years there have been a number of surgicalmethods developed for treating
breast cancer patients. Today, the emergence of new radiation technologies and techniques has removed, in large part, the need for breast removal along with associated
structures. Mastectomy involves the removal of breast tissue or more, and comes in
several categories:

1. Simple (or total) Mastectomy- Involves the removal of breast tissue from the
patient in the hope of removing the tumour mass and any sub-clinical tumour
cells. Sub-clinical being tumour cells not visible to the naked eye.
2. Modified Mastectomy- Involves removal of the breast tissue and axillary nodes.
3. Radical Mastectomy- Involves removal of the breast tissue, axillary nodes and
the chest wall muscle.
There exist several options for clinicians in the treatment of breast cancer. These
include: mastectomy, lumpectomy (or breast conservation surgery -BCT), radiation,
6
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chemotherapy, hormone therapy, or a combination of these. Mastectomy, lumpectomy,
and radiation are options that have been available for many years now and clinical
trials exist which have reached follow-up terms of five, ten, and in some cases twenty
years, yielding survival rates. One study (Veronesi et al., n.d.) with a median twenty
year follow, up gives the results of 701 women treated between the years 1973 to 1980
who had a breast tumour mass no greater than 2cm in diameter and no palpable
nodes. The women were randomly assigned to either a Halsted mastectomy (radical)
or lumpectomy with following radiation. The results indicate that there is no difference
in the 20 year survival rate between the two methods for women with small breast
tumours. It is of course important to note that the techniques used since then would
likely have been refined.
Another randomized trial (Fisher et al., 2002) of 1851 women with breast tumours
no greater than 4cm in diameter was carried out to determine whether mastectomy,
lumpectomy, or lumpectomy with radiation is appropriate for tumour control. In this
trial women had either negative or positive nodes, that is, type I or type II breast
cancer. The 20 year follow up showed no significant difference in total survival in
candidates regardless of method used.
One particularly large scale and noteworthy study was carried out by the Early
Breast Cancer Trialists’ Collaborative Group (EBCTCG) (EBCTCG, 2005). This
group had information on the treatment of 42000 patients where 24 types of local
treatments were compared. The study included analysis of trials which compared
radiotherapy versus no radiotherapy with BCT and mastectomy, reporting differences
in 5 year recurrence and 15 year survival rates. 25000 of the women had a large ( greater
than 10%) difference between therapy with and without radiotherapy. With BCT there
was a 19% reduction in 5 year recurrence and a statistically significant 5.4% reduction
in 15 year mortality. With mastectomy the reduction in 5 year recurrence was 17% and
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a statistically significant 5.4% reduction in 15 year mortality. It is interesting to note
that the EBCTCG study identified that the older radiotherapy techniques resulted in
a statistically significant excess contralateral breast cancer incidence ( risk ratio [RR]
1.18) in addition to a statistically significant excess of non-breast cancer mortality
mainly from lung cancer (RR 1.78) and heart disease (RR 1.27). These results indicate
why innovation and a constant search for new and improved techniques is necessary.

2.2

Breast Radiation Therapy Techniques

The purpose of breast radiotherapy is to eliminate cancer cells and prevent local recurrence. This goal has always been in conflict with a negative side effect of radiation
therapy, which is damage to normal tissues in the vicinity of the target. Over the last
several decades, technologies and techniques have been developed specifically so that
dose escalation can be provided to the target tissues, while sparing normal tissues.
That is, the therapeutic ratio of radiation therapy has been improved over the years,
for both breast radiotherapy and other sites, driven by the technological changes. In
breast radiotherapy the therapeutic ratio has mainly been improved by clever delivery
and better image guidance, dose escalation has not been a feature of breast radiotherapy. Techniques that have been used over the years in breast radiotherapy are as
follows.

2.2.1

Standard Tangents

Tangential beam radiotherapy is a staple technique used for the treatment of the
breast. In this technique, two approximately coplanar and opposed beams are set such
that they encompass the ipsilateral breast, and run tangential to the chest wall. This
technique uses either physical wedges or dynamic wedges to improve dose homogeneity
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within the breast. A previous study (Krasin et al., 2000) investigated the use of
standard tangent therapy. Twenty five consecutive patients were planned according
to 2D technique guidelines and then assessed using a 3D treatment planning system.
Results indicate that only 64% of patients received at least 95% of the prescribed
dose to 95% of the target. 80% of patients received maximum doses of 110% of the
prescribed or over. This study also showed the importance of using 3D planning over
2D techniques which marks a significant step in the development of breast radiotherapy.
3D planning requires a move toward the use of 3D CT scan data and away from 2D
simulation techniques.

2.2.2

Custom Compensators

Breast radiotherapy involving compensation has the ability to provide improvements
in dose homogeneity over wedged tangents. This process involves creation of an individual compensating device for each patient. The device has the effect of modifying
the radiation beam to create a homogeneous dose distribution throughout the breast
tissue. A paper by (Carruthers et al., 1999) shows an appreciable benefit to using
compensators. In this study the average dose heterogeneity using wedged tangential
fields was 12%. This reduced to 5% when using the optimisation technique, set out in
the paper. Custom compensators suffer from two main problems compared to more
advanced techniques: the time required to make the compensator, and contralateral
breast dose. The literature (Burmeister et al., 2008), (Borghero et al., 2007) shows the
benefit to normal tissues (contralateral breast) in moving away from physical beam
modifiers such as custom compensators or wedges, and toward intensity modulated
radiation therapy (IMRT). The benefit to normal tissues comes from the reduction in
scattered radiation incident upon the patient and improvements in dose homogeneity
when using IMRT in lieu of other beam modifiers. This is a particularly important
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consideration for young women, given the time for radiation induced cancer to affect
their life.

2.2.3

IMRT in the Treatment of the Breast

Strictly speaking, any form of beam modifier can be considered intensity modulation.
However, the term IMRT refers specifically to radiotherapy involving beam modification provided by the multileaf collimator. The use of IMRT in breast radiotherapy
has come to greater prominence in the last decade due to its advantages over other
forms of therapy. Kestin et al investigate the use of multiple fields in their paper and
the effect on homogeneity through 100 dose calculation points uniformly distributed
within the breast. These dose calculation points were verified with film dosimetry.
The paper compared three planning techniques as follows. Manual wedge planning,
with and without density correction, optimized wedges using beam weight optimization utility, and an IMRT plan using a differential superposition algorithm. Typically
6-8 segments were used for each patient with a static MLC field technique. Results of
this study were similar to others mentioned, increased dose homogeneity to the breast
with less severe hot spots.
IMRT not only provides advantage in dose homogeneity to the target volume ((Evans
et al., 2000) but also in sparing of normal tissues. In breast radiotherapy, the MLC is
a vital piece of technology in enabling the shielding of lung and heart tissue. From the
beams eye view in tangential therapy, the chest wall and lung follows a gentle curve
which meets breast tissue. This means that a critical normal tissue structure closely
abutts the target. With the use of the MLC, a complex field shape can be used to
escalate dose to the target and minimise dose to normal tissues, conferring therapeutic
advantage to the patient. This is the findings of several studies (Ahmed et al., 2008)
(Hong et al., 1999) in which doses to the heart, lungs and contralateral breast were
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studied using both conventional radiotherapy and a developed IMRT technique.
IMRT in breast radiotherapy is undertaken in two distinct ways:
1. Forward planned IMRT
2. Inverse planned IMRT
In forward planned IMRT, the treatment beam positions and field shapes are determined with the dose to the patient resulting from this. In inverse planned IMRT,
dose objectives to various structures can be set and an algorithm determines the beam
positions and field shapes required to achieve this.

2.3

Patient Positioning in Breast Radiotherapy

One thing not yet discussed is the effect that patient positioning has on radiotherapy.
During breast radiotherapy treatments, patients can be positioned either supine or
prone.

2.3.1

Supine

Supine positioning is a commonly used method for setting up patients in breast radiotherapy. Since therapy can last for four to five weeks it is logical to have the
patients assume a postion that provides comfort, in order that they be able to assume
the position day after day. Patient comfort is not the only consideration however.
Reproducibility of the patients anatomy is crucial for accurate and reliable therapy.
It has been noted in the literature that pendulous breasts tend to fall laterally and
posteriorly when patients are positioned supine (Pidcock & Rattray, 2002). This is a
problem for several reasons: not only may the breast not fall in the same way every
day, the breast also falls around the chest wall resulting in a greater breast separation
and volume of lung tissue in the field.
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Prone

One of the ways to avoid these problems is to have the patient treated in the prone position with the breast falling away from the chest wall through an aperture in a custom
couch assembly. A preliminary study (Mahe et al., 2002) was conducted in which 35
patients with large pendulous breasts (greater than a C-cup) underwent prone radiotherapy. The study demonstrated the feasibility of such a treatment with only three
patients unable to maintain the positioning required. These patients were characterised as obese. The study did indicate that prone positioning would make treatment
of the: mammary gland, chest wall, and lymph nodes, difficult or impossible. This
could potentially eliminate this therapy option for later stage disease. Another study
(DeWyngaert et al., 2007) with 91 patients also found prone radiotherapy feasible, and
reported heart and lung dose sparing with this technique. This study used accelerated
inverse planned IMRT to plan each patient in order to achieve ideal therapy conditions. Similar results were also reported by yet another study (Griem et al., 2003).
One study that does conflict with the results suggesting improved heart sparing is
by (Chino & Marks, 2008). This study found a shift in heart position toward the
anterior chest wall when patients are positioned prone. The study urges caution in
situations where the chest wall is part of the target or the timour bed is set deep near
the chest wall. Long term local control using prone breast radiotherapy was studied
by (Stegman et al., 2007). 245 women with early stage breast cancer and a median
follow-up of 4.9 years showed similar results compared to standard supine patients.
This is however only early stage and does not involve lymph node irradiation.

2.3.3

Breast Immobilisation

One option exists whereby many of the conditions for advantageous breast radiotherapy can be met. Breast immobilisation in the supine position:
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1. Allows little setup variation
2. Is tolerable for obese patients as there is no pressure on the thorax
3. Prevents the breast falling laterally and posteriorly
4. Reduces skin folds
5. Supine position allows for treatment of the chest wall, mammary gland, and
lymph nodes
Breast immobilisation does have two main patient specific costs incurred to achieve
the above listed therapy conditions. These are: the possible discomfort to the patient
in being immobilised, and the increase in dose to the skin due to the bolus effect of the
cast material. Any material put on the patient surface will have a bolus effect, and so
an ideal immobilisation cast reduces this effect as much as possible while maintaining
the requisite rigidity for immobilisation.
The literature contains several studies which have looked into the effect of immobilisation devices on skin dose. One study (Hadley et al., 2005) tested a similar
immobilisation product to the Orfit material examined in this thesis, the Sinmed thermoplastic mask. An Attix chamber was used for dosimetry with 6MV and 15MV
beams. The effect of the mask stretch on the surface dose for two separate mask models was systematically tested. Results for this study give useful normal incidence dose
information, the study is limited however in that it gives no information on the effect
of beam incidence or whether the stretching of the cast makes it unusable for immobilisation. Another study (Mellenberg, 1995) measured the effect of various thicknesses
of polyurethane and a perforated polycaprolactone thermoplastic mask (aquaplast) on
skin dose. This was measured with an extrapolation chamber following proceedures
formerly set-out by the Mellenberg and others (David E. Mellenberg, 1990) (Gerbi
& Khan, 1997). A different approach to breast immobilisation was studied (Latimer
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et al., 2005), where a breast ring was used to surround the breast while preventing
skin folds. This study reported on the practicallity of such an approach and suggested
good patient tolerance. Overall there seems to be a dearth of literature looking into
the utility of immobilisation casks in breast radiotherapy. The Orfit immobilisation
cask comes as a flat cross-hatched thermoplastic. In appearance it is akin to chickenwire. When the material is heated it can be deformed and upon cooling becomes rigid
such that it can be custom fit to an individual. The rigidity provides consistency in
breast position for each fraction of the patients radiotherapy treatment.

2.4

Treatment Regimens in Breast Radiotherapy

Maintaining the most current and effective treatment regimens for breast radiotherapy not only involves utilising new hardware and technology but also investigating
and implementing the most effective treatment regimens. It would be interesting to
investigate how the various treatment fractionation regimens impact on skin toxicity
and skin reaction. While exploring this is not within the scope of this study, it is important to note that tailoring treatment to an individual patient may not be just a case
of optimising beam weights or selecting from an array of published IMRT techniques.
Providing the best treatment in terms of tumour control and avoiding normal tissue
complication for an individual patient may go so far as selecting a different fractionation scheme. For example, several of these have been studied for irradiation of the
breast including 50 Gy in 25 fractions (Whelan et al., 2002), 42.5 Gy in 16 fractions
(Whelan et al., 2002) and 40 Gy in 15 fractions (Shelley et al., 2000). Treatment of
the breast with a boost to the tumour bed has also been studied with a treatment
consisting of 50 Gy in 25 fractions with an extra 16 Gy in 8 fractions to the tumour
bed (Bartelink et al., 2001). When there is a need to treat the axilla 45 in 20 Gy has
been examined (Chetty et al., 2000).
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Surface Dosimetry

Surface dosimetry in radiotherapy is complicated. This complication arises out of
the fact that when a typical photon beam is incident upon a patient the first few
millimeters experiences vastly different absorbed dose levels. As photons cross the
interface from outside air and into the patient they set in motion secondary electrons.
Progressively more secondary electrons are set in motion with depth into the patient
up to a point where the amount of electrons generated equals the amount stopping and
depositing their energy. It is at this point that charged particle equilibrium is said to
be reached. Consider a 6MV, 10x10cm2 photon beam normally incident upon a water
phantom at 100cm source to surface distance (SSD). Up until 0.1mm deep the depth
dose curve has a platuea which then changes to a steep gradient until 5mm depth
(Oborn et al., 2009). This causes complication in clinical surface dosimetry because
there are a number of products on the market which measure at slightly different
depths in this high dose gradient region. These products require differing preparation
of the dosimeters and readout methods. These products include:
1. Extrapolation chambers
2. Attix Chamber
3. Thermoluminescent Dosimeters (TLDs)
4. Film Dosimeters (radiographic or radiochromic)
5. Metal Oxide Semiconductor Field Effect Transistors (MOSFETs)

2.5.1

Extrapolation Chamber

Extrapolation chambers are a special type of the parallel plate ion chamber. The
main difference between the two dosimeters is that the extrapolation chamber can
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have a variable plate separation which enables it to measure zero water equivalent
depth (WED) doses. A discussion of the issues relating to extrapolation chambers can
be found in a previous study (David E. Mellenberg, 1990). Correction factors were
determined for the PTW 329 Markus-type chamber using the PTW 23392 extrapolation chamber as a benchmark to correct for over-response. These dosimeters are not
practical for clinical use due to their size and the significant bolus effect that they have
on the patient.

2.5.2

Attix Chamber

The Attix chamber (GAMEX/RMI Model 449) is a unique variety of parallel plate
ionisation chamber. The features of this detector are as follows (Attix, 1993):
1. Constructed almost entirely of solid water to minimise perturbation of the radiation field
2. 1mm plate separation gives dose measurements close to extrapolation chamber
without the inconvenience
3. Guard ring stops electron scattering
4. 48µm WED of measurement
5. Lesser polarisation effects compared to other parallel plate ionisation chambers
While the Attix chamber may be an accurate and reliable dosimeter for surface dose
measurements, it is not usable for in vivo dosimetry due to its bulk. Additionally, the
wide guard ring giving a total detector diameter of approximately 4cm makes small
field measurements impractical.
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TLDs

Thermoluminescent dosimeters are integrating dosimeters that work by having a high
concentration of trapping centers between the valence band and conduction band.
When radiation is incident upon the material, electrons are excited to these trapping
centers. The number of trapped electrons and holes is proportional to the amount
of electron-hole pairs created by the radiation. Reading the integrated dose involves
heating the TLD chip progressively until the thermal energy enables liberation of the
trapped electrons or holes to the conduction band (valence for holes). The electron
(or hole) will then migrate to a trapped hole (or trapped electron), and release energy.
Released energy in the visible spectrum is of interest to TLD readout. The exposure is
related to the number of electron-hole pairs, that is, the number of photons emitted by
the chip. The TLDs can be reused once they are annealed at high temperature. This
process involves prolonged high temperature to deplete any trapped holes or electrons.
TLDs are used commonly in radiation detection and measurement, a common
variant being the Lithium Flouride dosimeter. One study attempted to measure surface
dose by (Kron et al., 1996) using thin TLDs of varying thickness at the surface and
extrapolated back to zero depth. Compared to high resolution Monte Carlo obtained
with Geant4 code (Oborn et al., 2009), this method does not accurately measure dose
at 70µm.
TLDs for clinical surface dosmetry have one major disadvantage which is that they
do not provide real-time dose information to clinicians. Dose readout is a costly and
time consuming process performed some time after irradiation and intervening in a
dose delivery cannot be undertaken. Readings are however usually available prior to
dose delivery of the next daily fraction.
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Film Dosimeters

EBT GafChromic film (EBT, 2007) was widely used for dosimetry until 2009 and is
the film dosimeter of choice in this study. It has a WED of measurement at 153µ
when the beam is normally incident, is to a great extent resistant to ambient light,
and is robust in terms of handling. The literature contains exhaustive studies on how
to use this film type most effectively in a clinical setting (Devic et al., 2006) (Ferreira
et al., 2009) (Kalef-Ezra & Karava, 2008) (Lynch et al., 2006) (Martisikova et al.,
2008) (Soares, 2006).
An extrapolation method similar to that used with TLDs (Kron et al., 1996) was
used in a previous study (Butson et al., 1999) to obtain zero depth surface dose. The
results of this study agreed with uncorrected Attix chamber results within experimental error. While this method may work under simple beams and geometries, the
complexities clinical surface dosimetry use may discount the use of such a method.
Breast radiotherapy would be a case in point. Using a stack of films for skin dose
measurement may be physically difficult given the surface contour of the patient. Another point for consideration is the excess of surface dose that would arise due to the
bolus effect of the EBT film stack. It would not be ideal to increase the surface dose
in regions where you are using a surface dosimeter to investigate regions of suspected
high dose. Using EBT film in a single layer does have an advantage as the measurement depth at 153µ is representative of just below the basal layer of skin cells. This is
important, as it is the basal layer that replenishes skin cells more superficially as they
slough off. Furthermore, like the use of TLD’s, dose assessment is retrospective when
using film dosimeters however film does provide the advantage of a 2D dose matrix
over the TLD’s.
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MOSFETS

MOSFET detectors consist of a p-type silicon chip and metal gate separated by a
silicon oxide layer that has a source and drain attached. The gate supplies a bias
voltage sufficiently strong enough to allow current to flow between source and drain.
A negative bias supplied to the drain causes a positive charge to congregate in the
silicon oxide chip. As this charge accumulates the threshold (bias) voltage changes,
which can be related to dose (Knoll) (Gladstone et al., 1994) (Scalchi et al., 2005)
(Quach et al., 2000). As the threshold voltage changes, so does the sensitivity. It is
therefore prudent to perform intermittent calibrations of the MOSFET when using it
over a large dose range. Early versions of the MOSFET had an epoxy bubble which
was difficult to reproduce accurately, leading to variation in the WED from 0.04mm
to 0.15mm.
A special type of MOSFET designed at the CMRP (Center for Medical Radiation
Physics) is called the MOSkin. This detector has no inconsistent epoxy bubble over
the MOSFET chip, instead it has a polyamide layer, which is reproducible then hermetically sealed in plastic packaging (Hardcastle et al., 2008)). This dosimeter has a
WED of 70µ for a normally incident beam.
MOSFET dosimeters have been studied in the literature for their use as a surface
dosimeter due to this shallow depth of measurement and their practicality (Martin
et al., 1996) (Kwan et al., 2008). Advantages of using the MOSkin include:
1. Online dose read-out
2. dose signal can be viewed as dose is accrued using in-house developed software
MOSPLOT2
3. Measurement depth 70µm, the recommended measurement depth for skin dosimetry (ICR, n.d.), (ICRU62, 1999), (ICRP60, 1991)
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4. Requires inexpensive support electronics
5. Can be annealed and reused
Unlike film MOSkins do not provide a 2D dose array. Using the existing readout
system and MOSPLOT2 up to 10 channels can be read out simultaneously.

2.6
2.6.1

Dose calculation for treatment planning
Beam Modeling

Therapeutic radiotherapy requires treament planning on an individual basis in order
to tailor the most effective treatment regimen to each patient. Dose calculation for
treatment planning has undergone significant changes in the past thirty years. The
two main approaches to dose calculation are correction based methods and model
based. The correction based methods calculate dose in heterogeneous media by correcting the dose acquired in a similar homogeneous media. The article by (Ahnesjo &
Aspradakis, 1999) gives a comprehensive review of these techniques with reference to
early literature on the subject.
The most widely used method for dose calculation in radiotherapy is currently
through beam modelling with convolution/superposition algorithms. The process of
how this works is as follows. The planning computer software starts with a bremmstrahlung energy spectrum and mathematical expressions account for each relevant
(beam modifying) component of the linear accelerator. For example, Gaussian distributions are used to model scattered radiation and simple multiplicative factors determine jaw transmission.
Real-world linear accelerator beam data is acquired with an ion chamber in a water
tank. Based on the variables set in the beam model, dose distributions and profiles are
calculated throughout a virtual water phantom which is the compared to the real-world
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dosimetry. This process can be done automatically and iteratively by the TPS used
in this study (Pinnacle v8.0). The end result of this process is that a two dimensional
fluence profile resembling that of the real linear accelerator can be produced for any
required field arrangement.

2.6.2

Dose Calculation

The first step in dose calculation has the fluence profile incident upon the patient ray
traced through the patient CT data set. The electron density information is used to
determine the total energy released per unit mass (TERMA) array for that beam.
The TERMA array gives the energy released by primary particles in each voxel of the
patient. The energy released at each centre is then convolved with a dose depostion
kernel to determine the final dose distribution. This is the process deemed convolution/superposition (CS) (Mackie et al., 1985) (Ahnesjo, 1989). The deposition kernels
represent the spread and deposition of energy from secondary electrons from a primary
interaction site. The dose deposition kernels were originally generated through Monte
Carlo techniques and analytic functions can simply describe these kernels over a range
of energies which is how dose is calculated for a realistic polyenergetic beam (Mackie
et al., 1988) (Papanikolaou et al., 1993). The Pinnacle RTP uses an implementation of
convolution employing polar geometry where symmetry of dose deposition is used to
compute dose in radial paths. Hence the term collapsed cone convolution. Calculation
time is reduced compared with cartesian implemenations. Electron contamination
(EC) from the accelerator head is not accounted for in these calculation models as
they start at the patient surface. Hence this is then added to the convolution/superposition calculated dose. This is performed by means of an empirical mathematical
characterisation for the EC. This accounts for field size, distance from central axis,
and exponential fall-off into the phantom. Equation 2.1 gives the complete expression
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used by Pinnacle3 (Metcalfe et al., 2007) in modeling surface electron contamination.
Components in this expression are given in Equations 2.2 and 2.3.

Dec (F, r, d) = Dec (F, d) × OAef f ect

(2.1)

e−Kd − e−kDmax
1 − e−kDmax

(2.2)

Dec (F, d) = P (F ) ×

OAef f ect = eBr

2.7

2

(2.3)

Monte Carlo

Monte Carlo (MC) simulation is the gold standard for radiation dose calculation. MC
refers to the simulation of stochastic processes which in this case is the interactions
of radiation with matter. The application of MC techniques to radiotherapy involves
simulating up to billions of particles through a mathematically constructed linear
accelerator. This is performed individually, from their initial state, through every
interaction down to termination. Termination of the particle is invoked when its
energy falls below a preset level, usually when the energy is so low that the particle
has no chance of escaping the voxel in which it currently exists. MC has the ability to
account the physics processes in the energy range relevant to radiation therapy. These
include:
1. Compton scattering
2. Photoelectric effect
3. Pair production
The purpose of this process is usually to calculate absorbed dose in a patient CT
data set or a phantom for a given beam configuration. MC can be used over techniques
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like CS or real dosimetry when flexibility is required. MC can accurately calculate dose
in any arbitrary scoring volume unencumbered by real-world experiments involving
detector limitations or the limitations inherent to CS.

Chapter 3
Treatment Planning System
Surface Dose Calculations
3.1

Introduction

Treatment planning systems using deposition kernels are currently the world standard
for radiotherapy planning. This method of dose planning is appropriately fast and
accurate for clinical use in the majority of the patient volume . One region where
convolution/superposition (CS) is inaccurate is in the build-up region. This is because
current implemenataions of the kernel deposition method for dose calculation do not
account for electron contamination from the linear acceleraor (LINAC) head. It is
for this reason that an electron contamination dose is added separately to the dose
calculated by the deposition kernel to obtain total patient dose.
Errors in the TPS build-up dose calculation can be broken down into two main
areas: the beam model, and resolution limitations. Focussing on the first issue, the
determined beam model is fundamentally limited by the accuracy of the data on which
it is built. To create the beam-line model, data is collected in a water tank with an
ionisation chamber for a range of field sizes and with the various wedges used clinically.
24
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There is in reality many more beam configurations than can be reasonably acquired by
water chamber measurements, which form standards, upon which the beam is modelled
to best fit. One considerable problem with this method is the inaccuracy of using the
water tank and ion chamber setup, particularly in the build-up region. Measurement
complications include uncertainty in depth measurement, surface tension of the water
(Tailor & Tello, 1995) and volume averaging limitations of the finite sized dosimeter
itself (Zhu, 1999). At this institution, water tank measurements for beam modelling are
carried out using a CC13 ionisation chamber. This cylindrical chamber is a photon
detector approximately 6mm in diameter, which ensures CPE within the detector
volume, and as a consequence of it’s size, overestimates dose in the build-up region.
This is because the detector is measuring average dose in a high dose gradient region.
An additional complication using this chamber is that the effective measurement depth
is not necessarily in the centre of the detector. Correction factors applied to readings
for this dosimeter, according to the protocols (IAEA, 1987), include account for effects
such as temperature, pressure and humidity differences between measurement and
calibration. Additional corrections are applied for polarity effects and recombination.
These corrections ensure accuracy of the dosimeter after the build-up region but do
nothing to correct the major shortcomings of the detector in the build-up region. One
of the prominent methods to correct data in the penumbral region, but not done at
many institutions for the beam modelling data, is through use of a detector convolution
kernel (Higgins et al., 1995) (Sibata et al., 1991) (Garcia-Vicente et al., 1998). This
method can correct for the large measurement volume of the detector being insufficient
for electron detection. While this method can yield improved accuracy, the MonteCarlo method presented in this paper would negate the need for use of this method.
The second main problem with the build-up dose calculation arises from resolution
limitations. Patients are typically CT scanned at approximately 1mm resolution and
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so this forms a computational limit to the accuracy of skin dose. The partial volume
effects at the patient surface would make calculations where the dose grid resolution
is smaller than the CT resolution challenging, even if the computers had adequate
resources to handle the process. Currently, planning computers are limited by the
available memory and unable to calculate dose on a resolution small enough to indicate
skin dose. Time to wait for a calculation in the department is also a pressing practical
issue. Dose calculation grids in routine RTP currently approach 2mm3 at best.
An approach to achieve greater accuracy in planning computer build-up region
calculations is presented here. It is recognised the method introduced here will not
overcome all current RTP implementation issues such as the image and dose grid
resolution. A Varian 2100EX linear accelerator is modelled in the BEAMnrc package
with a phase space file created at 60cm from the source. This is then used as input for
the DOSxyznrc package, where a cuboid water phantom is created, and the calculated
dose profiles are used as input data for the planning computer physics model. Both the
old model built on ion chamber data, and the model built on MC data, are compared
to the Monte Carlo profiles from DOSxyznrc to observe any change to the planning
computer accuracy.
An alternative method would be to use Attix depth dose data. This could be
collected in the build-up region in solid water along with depth dose data in the
fall off region using a cylindrical chamber to create a beam model on pinnacle. The
restrictions are that small fields (less than 5x5cm) could not be measured and profile
data would be invalid due to the poor spatial resolution in the plane orthogonal to the
beam direction. Even the smaller volume chambers such as the new Markus chamber
could be used. Access to Attix data was available using (Oborn et al., 2009). The
surface doses are very similar to the Monte Carlo data as can be seen in Figure 3.1.
Using Attix data was also not attempted as collecting all the data would have been
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Figure 3.1: Comparison of Attix data and Monte-Carlo data in the build-up region.
This is for a 10x10cm field normally incident on a flat phantom. Doses are as percentages of dmax
very labour intensive, incrementing the detector across all the beam profiles for all the
required depths for modelling. Given the accuracy of MC data and the fact that it
could be readily produced, this was the data source of use.
Another important consideration for surface dose calculations is the effect that
alignment of the dose calculation voxels and the CT data set has on the calculation of
surface dose. This is investigated here by incrementally moving the dose calculation
voxels outside the CT data set to see how this impacts upon surface dose calculations
and calculations at increasing depths.
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Table 3.1: Monte Carlo simulation parameters used for linac commissioning
Simulation Parameters
Variable
ECUT
521 keV
PCUT
10keV
Boundary crossing
EXACT
e- Step
PRESTA-II
Brem. Split
Directional
3
Voxel size
2mm or 2x2x0.01mm for fine resolution calculations
Histories
BEAMnrc
20 million (approximately 2GB phase space)
Dosxyznrc
10 billion (for statistics)
Simulation Time
BEAMnrc
400 cpu hours
Dosxyznrc
600 cpu hours

3.2

Method

The linear accelerator model for MC simulation was constructed using the BEAMnrc
package (Rogers et al., 1995) (Kawrakow & Rogers, 2006) (Rogers et al., 2005) from
component modules according to Varian specifications. A phase space file was obtained
at 60cm below the source for jaw defined field sizes 5, 10, and 20 cm2 . These were
chosen to observe the accuracy in the modified planning computer model with varying
amounts of contamination electrons from the accelerator head. Pegs4 data was used
for the physics processes including low energy cross sections while simulating large
numbers of particles for accurate build-up calculations. Table 3.1 shows the parameters
used in the MC simulations for this study.
A 50cm3 water phantom was designed in the DOSxyznrc package for calculation of
the dose depositions. Voxels were chosen to be 2mm3 for pragmatic reasons as voxels
of this size were a computational limit on the planning computer hardware used and
this makes results directly comparable. MC dose arrays were calculated for 5 and
10cm2 field sizes at different angles of incidence. These include: 0◦ , 15◦ , 30◦ , 45◦ , 60◦
to the normal. The TPS beam modeling process only requires the normal incidence
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beam profiles as input, so these were extracted from the MC dose arrays for import
to the TPS beam modeling tool. These included a depth dose profile and cross-beam
profiles at depths 1.5, 5, and 10cm. The auto-modelling feature of Pinnacle was then
used to match the Monte-Carlo data to obtain a new TPS beam model. This was
used to calculate dose distributions for 5cm2 and 10cm2 fields, at the various angles
of incidence onto the phantom. The beam model based on the ion chamber results
(original model) was also used to calculate dose for comparison. These TPS calculated
dose arrays were then exported in RTOG format to be imported into CERR for data
extraction and comparison.
The effect of dose voxel placement with respect to the phantom was also investigated. This was performed by setting up a 5x5x10 voxel dose cube with a voxel
resolution of 2mm. The dose cube was 10 voxels deep in the direction of the beam
line in order to extend as far as dmax. It was initially positioned such that the entire
dose cube sat just below the surface of the phantom with the edge of the CT data
set coinciding with the edge of the dose cube. The field size was 10x10cm, set to a
point at 1.5cm depth and normally incident upon the phantom. Measurements were
obtained every 1mm from the surface down to dmax (1.5cm). The dose cube was
then incremented up toward the beam and out of the phantom by 0.2mm and the
calculations were retaken. This was repeated until the dose cube had moved so that
the first plane of voxels were outside the phantom, ie 2mm as shown in Figure 3.2
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Figure 3.2: Position of dose calculation voxels (with resolution 2mm cubed) relative to
phantom. A) Initial position with dose voxels and CT voxels aligned B) 5x5x10 voxel
cube moved up by 0.2mm C) Final postition of voxel array having moved exactly one
voxels thickness partially out of the CT phantom. Note no CT voxels drawn and only
two calculation voxels drawn for clarity.
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Results
Monte Carlo Commissioning

Figure 3.3, Figure 3.4, and Figure 3.5, shows Monte Carlo calculated dose distributions
matched well with CC13 ion chamber data for the field sizes used in the study. This is
a common benchmarking exercise to ensure input fidelity (eg. electron beam energy,
flattening filter geometry etc.) prior to the use of the MC in other experiments. Ion
chamber data had higher entrance dose as expected due to the size of the detector
averaging dose in a high dose gradient region. Monte Carlo cross beam profiles also
had more narrow penumbra that the ion chamber data, again this is probably due to
the size of the ion chamber used to take measurements.
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Figure 3.3: Comparison of Monte Carlo and ion chamber depth dose data. (a) is for
a 5cm2 field and (b) is for a 10cm2 field
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Figure 3.4: Cross-beam profile comparisons of Monte Carlo and ion chamber data.
This is for a 5cm2 field (100cm SSD) at different depths. (a) is in the X direction, (b)
is in the Y direction
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Figure 3.5: Cross-beam profile comparisons of Monte Carlo and ion chamber data.
This is for a 10cm2 field (100cm SSD) at different depths. (a) is in the X direction,
(b) is in the Y direction
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Using Monte Carlo to Improve Convolution/Superposition Based Beam Modelling

Figure 3.6 through to Figure 3.8 show beam profiles at the phantom surface for a
5x5cm2 field with increasing angle of incidence upon the phantom, starting at normal
incidence and incrementing by 15◦ with each graph. Figure 3.9 through to Figure 3.11
shows the same data for a 10x10cm2 field. Evident in the figures is the improvement
that using Monte Carlo data for the beam model has made to the planning computers
ability to calculate surface doses for simple field arrangements. The beam modelled
using ion chamber data gives significantly higher doses than the revised model under
all the tested field arrangements. This is expected since the ion chamber measures
higher doses higher than actual in the build-up region due to its large size. At higher
angles of incidence, the revised model calculates higher doses than the MC data in
the dose profiles on the side of the phantom closest to the entrant beam. While
the cause of this is unknown, the effect may be improved if Pinnacle TPS allowed
(or required) the input of variable beam incidence data into the modeling process.
Another noticable feature in the figures is the Monte Carlo simulated tails (the section
of low dose outside the penumbra) being higher than those calculated in Pinnacle.
This could be a consequence of the iterative modeling process sacrificing accuracy on
the surface to better match the model to data at depth. It can also be seen that
the model calculates the tail dose more accurately on the far field side. This is most
notable for the 10x10cm2 field.
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Figure 3.6: Comparison between Monte Carlo data and Pinnacle beam models built
on both Monte Carlo data and Ion chamber data. This data is for a 5x5cm2 field
incident: (a) normally (180◦ ) (b) 15◦ to the normal
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Figure 3.7: Comparison between Monte Carlo data and Pinnacle beam models built
on both Monte Carlo data and Ion chamber data. This data is for a 5x5cm2 field
incident: (a) 30◦ to the normal (b) 45◦ to the normal
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Figure 3.8: Comparison between Monte Carlo data and Pinnacle beam models built
on both Monte Carlo data and Ion chamber data. This data is for a 5x5cm2 field
incident at 60◦ to the normal
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Figure 3.9: Comparison between Monte Carlo data and Pinnacle beam models built
on both Monte Carlo data and Ion chamber data. This data is for a 10x10cm2 field
incident: (a) normally (90◦ ) (b) 15◦ to the normal
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Figure 3.10: Comparison between Monte Carlo data and Pinnacle beam models built
on both Monte Carlo data and Ion chamber data. This data is for a 10x10cm2 field
incident: (a) 30◦ to the normal (b) 45◦ to the normal

3.3. Results

41

Figure 3.11: Comparison between Monte Carlo data and Pinnacle beam models built
on both Monte Carlo data and Ion chamber data. This data is for a 10x10cm2 field
incident at 60◦ to the normal
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Effect of dose voxel placement relative to CT dataset

Table 3.2 shows the effect of dose calculation voxel and CT voxel coincidence. As
described in the caption, the values across the top are the distance from the top of
the dose calculation voxel to the top of the CT data set voxel. Successive columns are
the calculated doses at a distance below the surface (as designated in the left-hand
column) as the dose calculation voxel is moved incrementally outside the phantom. By
the time it has moved 0.2cm as shown in the second last column, the first dose voxel
(of the ten in the direction of the beam-line) has moved completely outside the CT
voxels. Recall that the voxel resolution is 2mm cubed. It is clear that dose reported
at a given depth relies to some extent on dose calculated in adjacent voxels. This
is indicated by the difference between the calculated doses in row 1/column 1 and
row 1/column 11. The only difference between these two calculation conditions is that
there is a calculation voxel full of air above the lower calculated dose. It is easiest to see
the effect of dose calculation involving interpolation between adjacent voxels here as
there are no partial volume effects at play. The partial volume effect is marked for the
surface dose calculation where the voxels are displaced 0.12cm toward the beam. The
effect that the dose calculation interpolation between voxels has is notable, affecting
calculations down toward 1cm.
The sensitivity of the dose calculation to dose voxel and CT voxel alignment can be
appreciated in Table 3.3. This shows the standard deviation of the dose calculations
at different depths in the CT phantom for the different voxel positions. It is not
surprising that the greatest sensitivity of calculation to positioning is at the phantom
surface.

0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
1.1
1.2
1.3
1.4
1.5

Depth (cm)

Distance from
0.00
0.02
61.80 59.95
62.07 62.01
70.95 70.86
79.78 79.02
85.09 84.76
90.14 89.61
92.55 92.39
94.93 94.91
96.52 96.62
98.11 98.14
98.82 98.82
99.50 99.46
99.97 99.98
100.44 100.37
100.34 100.31
100.24 100.27

the top of the
0.04
0.06
58.32 56.41
62.05 62.21
70.70 71.37
78.19 78.45
84.32 84.46
89.04 88.73
92.21 92.15
94.81 94.66
96.65 96.63
98.06 97.94
98.81 98.80
99.45 99.43
99.96 99.94
100.26 100.15
100.25 100.19
100.28 100.27

dose calculation voxel
0.08
0.10
0.12
53.88 53.02 6.73
62.50 63.17 35.04
72.68 73.27 59.16
79.07 78.86 68.62
84.67 84.57 78.00
88.58 88.36 83.28
92.21 92.12 88.04
94.45 94.32 91.03
96.57 96.44 93.77
97.85 97.74 95.70
98.91 98.92 97.30
99.50 99.43 98.10
99.99 99.93 98.76
100.11 100.01 99.01
100.16 100.09 99.30
100.29 100.28 99.70

to the top of
0.14
0.16
12.37 16.88
40.50 48.62
60.77 65.42
70.59 74.55
78.78 81.27
84.44 86.66
88.90 90.20
91.83 93.02
94.29 95.12
96.16 96.83
97.51 97.97
98.29 98.70
98.85 99.14
99.14 99.41
99.50 99.77
99.91 100.17

the CT
0.18
24.30
55.53
67.76
76.66
83.12
88.43
91.47
94.08
95.84
97.60
98.44
99.13
99.46
99.71
100.10
100.49

data set voxels (cm)
0.20
0.4
32.02
32.02
62.07
62.07
70.96
70.96
79.78
79.78
85.09
85.09
90.13
90.13
92.54
92.54
94.93
94.93
96.52
96.52
98.12
98.12
98.81
98.81
99.49
99.49
99.73
99.73
99.97
99.97
100.35
100.35
100.69
100.69

Table 3.2: Dose calculations showing partial volume effects. Values are dose percentages of the prescription dose for the
beam, 100cGy at dmax
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Table 3.3: Variation in dose calculation
Depth (cm) Standard Deviation
0
21.34
0.1
10.06
0.2
4.78
0.3
3.84
0.4
2.58
0.5
2.25
0.6
1.58
0.7
1.36
0.8
1.04
0.9
0.86
1
0.59
1.1
0.52
1.2
0.48
1.3
0.49
1.4
0.36
1.5
0.26
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Discussion

TPS surface dose calculations were seen to improve when using MC data as input for
the commissioning process in lieu of ion chamber data. The results show that Pinnacle
is reasonably capable of accurate surface dose calculation provided that accurate data
is given as input to the beam model. This is not to say that dosimeter data cannot
be used as input to achieve accurate surface dose calculation, only that the cylindrical
type used in this experiment is not ideal. A parallel plate ionisation chamber could be
used as input for the beam model if the requisite measurements are taken. This would
however be a long process needing stepwise movement across all fields ie. for all the
required field sizes and depths for the input data. For this reason, MC data was used
instead.
It is also worthy of note that while the pinnacle match to the cylindrical ion chamber
data is included in the graphs that include oblique incidence, no conclusions should
be drawn about how these profiles change with beam angle. This is because the beam
model is created using the detector at normal incidence only and in the high dose
gradient region.
The TPS calculated doses were seen to accurately reflect the MC simulated dose
which in this study, was the average dose deposited across a 2mm voxel. The ability
to calculate accurate skin dose with TPSs will be restricted however by several factors.
This first of these is the course CT scan resolution. Currently patients are scanned
at approximately 1mm resolution. Therefore, the closest that a TPS surface dose
calculation will come to a true skin dose calculation is an average dose over the first
1mm of tissue. This study used 2mm3 voxels for calculation as the planning computer
hardware lacked the specifications to make finer dose calculations. The second problem
preventing a TPS from calculating skin dose is the partial volume effect at the interface
between outside air and the patient. Not only is this a problem when a CT voxel is
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partially including air and tissue but also when the calculation voxel includes both
the tissue/phantom and air. The latter problem was investigated in flat phantom
geometry and shown to have an appreciable effect on surface dose calculations. For
partial voluming effects not to adversely affect a surface dose calculation, the resolution
would have to be small compared to the average depth on which a measurement is
required for complex geometries. In the study using MC data as input to the TPS,
a flat phantom is used with the calculation voxels lining up with the CT voxels so
partial voluming is not a problem. For patient geometries with a curved air/patient
interface, calculating average dose in the first 2mm3 voxel layer in the patient would
likely involve a portion of air in the calculation volume having the effect of lowering
the average density and providing misleading dose information. A greater technical
challenge which prohibits the calculation of skin dose using convolution/superposition
is the complexity of electron contamination. Electron contamination is dependent on
many factors, primarily field shape and beam modifying devices. To enable accounting
for it in a convolution/superposition based dose calculation engine an empirical or
other model needs to include all complex field arrangements.

3.5

Conclusion

Using Monte Carlo in lieu of cylindrical ion chamber data as input for beam modeling
in a convolution/superposition based TPS can improve its surface dose estimates in a
flat sloping phantom. The match is likely to be less effective in complicated patient
surface geometries. The main challenge remaining is dose dose voxel resolution being inadequate providing partial volume effects which confound accurate calculation.
While shell geometries have been implemented in several Monte Carlo codes for curved
surfaces they are not yet implemented in RTP where cubic voxels are generated. Cubic voxels have some practical advantages in RTP including alignment with CT cubic
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Chapter 4
The effect of Immobilisation
material on skin dose
4.1

Introduction

There is not currently a great amount of published literature regarding the impact of
immobilisation materials on breast surface dose. This information could however prove
valuable to clinicians, for reasons discussed in the literature review section. In this
chapter of the thesis, the effect of a particular immobilisation cast (Orfit) on surface
dose, is investigated. This is performed through an anthropomorphic phantom study
using EBT Gafchromic film and MOSkin dosimeters.

4.2

Methods

A rigid anthropomorphic phantom was employed for dosimetry in this study. The
phantom was constructed of tissue analogue material with removable breasts, such
that a range of sizes can be used for dosimetry as required. The breast size used
for this study was D-size, since pendulous breasts are roughly this size and above.
48
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With the D-sized breasts in place, the phantom was scanned on a Siemens Sensation
Open CT for radiotherapy treatment planning. An IMRT plan was created using
the P3IMRT tool in the Pinnacle treatment planning system (v8.0, Philips Medical
Systems, Fitchburg WI USA). The plan consisted of four fields in total; both an open
and a modulated field from two opposed gantry angles (311◦ and 135◦ ). The goal of
the modulated field IMRT optimization was to minimize hot dose spots throughout
the breast. Open fields of high beam weight ( 80%) were included to ameliorate
the movement effects during treatment and in general deliver as homogeneous a dose
distribution throughout the breast volume as possible. The dose distribution in a
transverse slice is shown in Figure 4.1.
The phantom was irradiated using a Varian 2100C (Varian Medical Systems, Palo
Alto CA USA) linear accelerator, with the phantom positioned upon an Alpha-cradle
(Smithers Medical Products, Inc., OH USA) in the supine position. An Orfit immobilization device was created for the phantom. The phantom was aligned using room
laser alignment to markers placed at the time of simulation.

Figure 4.1: Axial view of the anthropomorphic phantom with opposed tangents
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Film Dosimetry

EBT Gafchromic film was used (International Specialty Products, NJ USA). The
active layer of the film is at a water equivalent depth (WED) of 153µ (Devic et al.,
2006) and is being used to measure dose slightly deeper than what is considered as skin
dose by the (ICRP60, 1991) and (ICRU39, 1985) recommendations . This dosimeter
was used for its ability to obtain 2D dose maps. It is also interesting to obtain dose
measurements slightly deeper than 70µ as the epidermal layer of the skin can vary in
thickness (ICRP23, 1975). The film was prepared by cutting into 1.5cm by 25cm strips
for placement on the phantom surface at points of interest. A set of calibration films
were irradiated at the time of experimentation and all films scanned approximately 24
hours later. This was to take into account sensitivity differences between batches of
film and eliminate the optical density dependence of readout on time after irradiation
(Soares, 2006). Film was scanned using an Epson v700 (Epson America Inc., Long
Beach, CA) scanner in reflective mode in the center of the field, as this improves
scanner uniformity (Kalef-Ezra & Karava, 2008). Scans were performed at 16 bit per
colour channel and 72 dpi. Scanning at greater resolution than 72 dpi provides no
great advantage (Martisikova et al., 2008). Data was taken from the red channel only,
as this corresponds closely to the maxima on the absorption curve for Gafchromic
films, achieving greatest scan sensitivity. All films were used within the manufacturer
specified dose range. Calibration and measurement films were scanned in the same
orientation to minimize this source of error.

4.2.2

Film Placements

Film was placed on the phantom surface in the medial to lateral direction as shown in
Figure 4.3. The first strip of film went from the manubrium, across isocenter, toward
the axilla. The second strip went from the apex of the contralateral breast, across
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the sternum, over the apex of the ipsilateral breast, and down to the Anterior/Posterior simulation tattoo. The third strip went from approximately the xiphoid, along
the inframammary fold region and down the chest wall laterally. The film outlines
were drawn on the phantom to permit accurate placements of further film as required
(for each tangential beam). These points for film dosimetry were chosen as they are
reported sites of skin toxicity for breast irradiation and therefore of clinical interest.

4.2.3

MOSkin Dosimetry

MOSkin dosimeters were used to obtain point dose measurements at various positions
of interest also measured by the film. The MOSkin detector has a WED of measurement of 70m from the front side, the ICRP defined depth of the radiosensitive basal
layer in the skin (ICRP60, 1991). A feature of the MOSkin is that it can be read-out
it real-time, resolving the contribution of each individual field to the total dose distribution. A detailed description of the MOSkin detector construction can be found in a
previous report (Hardcastle et al., 2008). The MOSkins with measurement positions
shown in Figure 4.4 were read-out using a reader developed in-house at the Center for
Medical Radiation Physics (CMRP), University of Wollongong, Australia as seen in
Figure 4.2.
Calibration of the MOSkin dosimeters was undertaken at 100cm source to surface
distance, with the dosimeter at dmax (1.5cm) using a 10x10cm2 field before and after
measurements. MOSFET detector sensitivity can change with absorbed dose, therefore greater accuracy in measurements can be obtained by using an average of the
calibration factors before and after measurements are obtained. The MOSkins were
calibrated in both face up and face down arrangements to take into account varying
sensitivity in the MOSkin’s response to radiation incident from the top and the bottom
faces. For all subsequent MOSkin measurements, the appropriate calibration factor
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Figure 4.2: MOSkin detector readout system. Developed in-house at the CMRP,
capable of reading 10 MOSkins per box simultaeously (2 channels per plug)
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was selected based on the direction of incident radiation. All MOSkin measurements
were repeated three times to obtain measurement variance.
MOSkins were taped on the phantom at carefully measured intervals along the film
dosimetry positions to obtain real-time dosimetry and point doses for comparison with
film. Data for detectors 1 through 4 and 13 through 16 was taken simultaneously and
data for Detectors 5 through 12 was taken simultaneously (see Figure 4.3). Care was
taken to have no air gaps behind the dosimeters.
The film and MOSkin measurements were performed in separate irradiations to
prevent the interference of one dosimeter with the other. The treatment involved two
fields opposed tangential to the chest wall, with multiple segments within each field.
Therefore, film and MOSkin data was taken for each gantry angle, with and without
Orfit, so that entrance and exit dose to the dosimeters could be separated.
All MOSkin error bars includes error attributed to: the calibration factor variance,
and repeat measurement statistics. When combining MOSkin doses from each field to
obtain total plan dose, the MOSkin error bar also includes the error in adding these
dose measurements together. In the real-time MOSkin dose figures the progressive
total error is represented by an error bar with an end-cap. In the figures comparing film
measurements with the MOSkin measurements, the error bars are inclusive of all errors.
Errors were combined in the conventional way, through the sum of squared ratios
for product relationships, and sum of squared errors for addition of factors. Error in
positioning of the MOSkins is not accounted for in the error bars, though it is estimated
to be 1mm in each direction. Only positioning error in the medial to lateral direction
would be appreciable on the figures by comparing MOSkin dose measurements to the
film measurements. Film measurements were not taken in the superior to inferior
direction for comparison with MOSkins to appreciate mispositioning error.
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Figure 4.3: Detector locations. Black strips represent approximate film locations,
white spots indicate approximate MOSkin points.
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Figure 4.4: MOSkin dosimeters taped down on the phantom using Micropore noting
that the Micropore does not cover the sensitive volume of the detectors
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Variation of Surface Dose with Cast Thickness and Incident Angle

A supplementary study was undertaken in which the variation of the MOSkin-measured
surface dose with cast thickness and incident beam angle was measured. This was performed in flat phantom geometry with beam angles incident at 15◦ increments from 0◦
up to 75◦ , with the final increment smaller and the beam angle at 85◦ from the normal.
Measurements were not taken with EBT film as the film used for the other studies ran
out and was no longer in production. Cast thickness was varied by stretching as in
clinical use where the cast is stretched over the patient surface. Three cast thicknesses
were used. Un-stretched Orfit was used for reference with a thickness of 2.6mm as well
as Orfit (called ’thick’ in results section) stretched to be 1.5±0.2mm thick and Orfit
(called ’thin’ in results section) stretched to be 1.2±0.1mm thick. Once stretched the
Orfit started to develop holes as intended from the perforations made in the manufacturing process. For the two stretched casts these holes were 2.2×1.8mm±0.1mm and
6.2×2.3mm±0.1mm respectively. The surface dose was measured with the MOSkin
without a cast and also under both casts positioned under the stretch holes and under
the Orfit material.
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Results
Calibration

Calibration films were irradiated in the following increments: 0, 25, 50, 150, 200, 250,
300, 350, 400 cGy. A sixth order polynomial was fitted, giving the relation between
optical density (OD) and known irradiation dose. The polynomial fitted predicted the
known calibration relationships between OD and dose to within 1.1%, worst case, for
the previously listed doses.

4.3.2

Film Colour-Wash Images

Figure 4.5 gives a snapshot overview of the EBT film results. (a) shows the normalised
2D dose washes for the EBT film without the immobilisation cast present. Films were
calibrated as in the previous section and then deformed to a picture of the phantom.
in Adobe photoshop. It works by converting the phantom picture to greyscale and
determining where an artificial light source could have come from in order to gauge
the 3D shape of the object. It is important to recognise that the film dose image
does not correspond perfectly with the point of measurement on the surface. This is
a consequence of error inherent in the deformation process. The information intended
to be conveyed is an appreciation of the dose increase between (a) and (b), as a result
of the immobiliation cast. The cruciform patterning on (b) is a result of the Orfit
immobilisation cast structure.

4.3.3

MOSkin Dosimetry

Figure 4.6 shows the realtime MOSkin data for detectors 1 and 2 as shown in Figure
4.3. The blue data points show the dose measured by the MOSkins as a function of
time under the 135◦ open field. Lime green data points are for the 135◦ modulated
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Figure 4.5: Film measurements (a) without the immobilization cast present, (b) with
the immobilization cast present
field. Magenta data points are for the 311◦ open field. Cyan data points are for the
311◦ modulated field. Each of the fields were delivered separately and a thirty second interval was observed after the end of irradiation until the MOSkin acquisistion
stopped. This is standard practise as it allows the MOSkin to stabilise for readout. In
these figures there is also a ten second interval between starting the MOSkin acquisistion and recieving dose. After the MOSkin acquisistion was started in each case, this
ten second interval was observed until beam-on to represent realistic treatment breaks
due to field and gantry changes. This also allows checking to see if the MOSkin is stable before it recieves any dose. The total dose for each treatment is therefore obtained
by adding dose from each field to the dose from the previous field in post-processing.
Each of the graphs can be seen to have two total therapy data sets. Invariably, the
data set with the higher total dose is the surface dose when the Orfit immobilisation
cast is in place over the MOSkins. If the measurement is on the surface where the
beam is entering the phantom, the Orfit acts as bolus providing build-up. If the measurement is on the exit side of the phantom then it provides back scatter, hence the
measurements with Orfit present will always be higher within the field. Out of the
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Figure 4.6: Realtime data for detector placements 1 and 2
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field measurements may have a different effect. In this region there could be radiation
low enough in energy such that the immobilisation cast actually provides shielding.
The zero gradient plateaus are during time gaps between field deliveries. Figures 4.6
to 4.13 show real-time acquisition using MOSkins in combination with CMRP MOSPLOT2 acquisition software. The data file is transfered to and Excel spreadsheet and
graphs of dose (y-axis) vs time (x-axis) is presented. Where the gradient dose vs time
gradient is linear in the figures the detector is under the influence of an open field.
Where the gradient is irregular in the figures the MLC is moving above the detectors
to provide the numerous IMRT segments. Figure 4.6 shows that Orfit has little effect
on the surface dose for the fields from beam angle 135◦ . The Orfit does however have
a large effect on the surface dose when the gantry angle is at 311◦ . This is because in
this situation the Orfit is acting as a bolus material, escalating dose to the surface.
Detector 5 in Figure 4.8 does not show any surface dose escalation provided by the
Orfit. This detector was placed in such a position that the beam ran nearly parallel to
the phantom surface. Under such obliquity there is little to no build-up at any given
point on the surface except where the beam first intersects the air/phantom interface.
When looking at Detector 6 in Figure 4.8 through to Detector 12 in Figure 4.11,
the dose escalation effect of the Orfit has progressively less effect on the 311◦ fields
and more on the 135◦ fields. This is because these detectors range from the medial
ipsilateral breast surface, over the apex, and down the lateral breast wall. They are
therefore progressively changing from recieving entrance dose from one gantry angle
(311◦ ) to the other (135◦ ). Detector 5 also shows a proportionally larger error than
the other detectors. This is because the repeat measurement error is comparatively
larger for small doses with MOSkins.
It can be seen in Figures 4.10 and 4.11 that the modulated field from gantry angle
135◦ delivers more dose to the MOSkins going from Detector 9 through to Detector
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Figure 4.7: Realtime data for detector placements 3 and 4
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Figure 4.8: Realtime data for detector placements 5 and 6
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12. The reason for this is obvious when considering the function of modulated fields in
breast radiotherapy, and the positions of these detectors. In breast radiotherapy, the
function of the modulated field is to boost dose to the posterior section of the breast
where the radiological thickness is greater. Detector 9 is placed near the apex, the
remaining three detectors are placed progressively more laterally and posteriorly on
the phantom, and hence recieve greater dose from the modulated field.
As previously discussed for MOSSkin measurements, error bars for Figures: 4.6
through 4.13 include error attributed to the calibration factor used, and repeat measurement statistics. The final larger error bar for each field represents the total dose
error up to that point. That is, it accounts for error in the addition of dose from each
field to the fields preceeding it.
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Figure 4.9: Realtime data for detector placements 7 and 8
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Figure 4.10: Realtime data for detector placements 9 and 10
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Figure 4.11: Realtime data for detector placements 11 and 12
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Figure 4.12: Realtime data for detector placements 13 and 14
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Figure 4.13: Realtime data for detector placements 15 and 16
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EBT Film Dosimetry

Figure 4.14 through to Figure 4.17 gives integrated MOSkin and film measurements.
Line profiles represent the film data while point measurements are the MOSkins. The
blue dashed line is the surface dose when the Orfit immobilisation cast is present.
The green solid line is the surface dose when the immobilisation cast is not present.
Red diamonds are the MOSkin data poins when the immobilisation cast is present.
Magenta diamonds are the MOSkin data poins when the immobilisation cast is not
present. Inset tables give dose values for corresponding film and MOSkins data points
in the respective figures for ease of comparison.
Figure 4.14 (a) gives build-down surface dose information for the superior film strip
as shown in Figure 4.5. Specifically, this is the surface dose given by the open and
modulated field from gantry angle 135◦ . It can be seen in the data that the presence
of the immobilisation cast causes an increase in the exit surface dose. This is because
the Orfit provides backscattered radiation to the surface.
The MOSkin dose measurements are consistently lower than the film results. At
normal incidence, MOSkins are measuring build-down at 70µm whereas the film is
measuring build-down at 153µm. Under oblique conditions such as encountered in
breast radiotherapy the effective build-down measurement depth is greater but the
MOSkins remain measuring at a lower build-down depth than the film. For this film
strip location, the angle of beam exiting the surface is approximately 45◦ from the
normal at the central axis.
When looking at Figure 4.14 part (b), the most notable feature is the greater
difference between the two film doses compared to (a), and the modulation in the
measured film dose when the Orfit is present. In part (b), the measured dose values
are for entrance surface dose becuase the gantry angle is 311◦ . Since dose measurements
are being taken in the high gradient region of the build-up curve, any small increase in
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WED has a large impact on measured dose. The modulation in the film measurements
is a result of the Orfit structure. During the manufacturing process the Orfit is holepunched, it is this that provides the modulation in the film measurements. It can also
be seen that the film dose under an Orfit hole is higher than when the Orfit is not
present. This is probably due to scattered radiation from the Orfit structure.
Figure 4.15 is a more complicated situation than in Figure 4.14. This is because
the phantom contour is no longer approximately level, this dosimetry region includes
the breast contour. Data in this Figure is for the central film strip prosition shown in
Figure 4.5. Part (a) again gives the surface dose attributed to the 135◦ gantry angle
For this gantry angle, between 0cm and 25cm is surface dose measurement on the
contralateral breast across to the ipsilateral apex which is exit dose. From 25cm to
50cm surface dose measurement from the ipsilateral apex down the lateral breast wall,
hence this represents entrance dose. The angle of incidence between the dosimeters
and the incident beam varies significantly throughout these measurements. As in
Figure 4.14 the effect of the Orfit on buildup dose can be observed in addition to
the modulation from the Orfit holes. On the entrance side (lateral breast wall) the
MOSkins have a consistently lower dose than the film when there is no Orfit present.
This is due to the dosimeters different WED. When the Orfit is present, the MOSkins
measure anywhere between the peaks and troughs of the corresponding film result.
This is due to the complicated nature of the measurement. The MOSkins were placed
either: fully obscured, partially obscured, or not obscured by the Orfit according to
the beams-eye-view. Positioning the MOSkins relative to the Orfit deliberately to any
one of these conditions was not practical and so a range of dose measurements between
the corresponding film measurements was expected.
Measurements shown in Figure 4.16 is for the inferior film strip prosition shown in
Figure 4.5. Part (a) follows previous figures in showing surface dose attributied to the
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135◦ gantry angle while (b) shows the data from gantry angle 311◦ . The phantom surface for these cheast wall measurements is curved and both beams have their posterior
field edges cutting chords through the external contour. The result of this complicated
arrangement can be seen in part (a). From 0cm to approximately 10cm exit surface
dose is being measured. At approximately 10cm a notable divergence between the
Orfit and no-Orfit measurements can be seen. From here until approximately 17cm
along the film in the medial to lateral direction the Orfit acts as bolus making both
film and MOSkin measurements take place at a greater WED. The EBT film and
MOSkin measurements are in close agreement when the Orfit is not present probably
because the beam is highly tangential to the surface. When the Orfit is present, the
EBT film and MOSkin measurements are not in close agreement. This could be due
to misplacement of the MOSkins. When looking back at the colourwash images in
Figure 4.5 at the beginning of the chapter, a large dose gradient for the inferior film
strip can be seen in the superior/inferior direction.
Figure 4.17 shows the total surface dose for Figures 4.14 through to Figure 4.16.
This is obtained by adding the dose at each position in part (a) and part (b) for
each figure. When observing the total surface dose measurements it should be noted
that the prescription dose for this treatment is 200cGy to isocentre and 200±5% over
the breast volume. Average in-field EBT film surface dose increases due to the Orfit
immobilisation cast were: (a) (34.5 ± 17.5)% in the superior film strip, (b) (25 ±
18.3)% across the breast apex, (c) (17.6 ± 10.3)% inferior to the breast. Note that the
errors for the in field dose increases are large as the areas that are averaged are also
large. Within these averaged areas the beam obliquity changes substatially affecting
surface dose in addition to the varying thickness of the stretched Orfit having an effect
on measured surface dose. The dose increases for the MSkins and film increases at the
same point can be seen in the tables inset to the figure of interest.
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Figure 4.14: Surface dose from two individual gantry angles, the addition of dose from:
(a) Gantry angle 135◦ and (b) Gantry angle 311◦ . Adding (a) + (b) gives the total
treatment dose in Figure 4.17 (a) and is the total dose taken by line profile through
the superior film strip shown in Figure 4.5
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Figure 4.15: Surface dose from two individual gantry angles, the addition of dose from:
(a) Gantry angle 135◦ and (b) Gantry angle 311◦ . Adding (a) +(b) gives the total
treatment dose in Figure 4.17 (b) and is the total dose taken by line profile through
the middle film strip shown in Figure 4.5

4.3. Results

74

Figure 4.16: Surface dose from two individual gantry angles, the addition of dose
from: (a) Gantry angle 135◦ and (b) Gantry angle 311◦ Adding (a) + (b) gives the
total treatment dose in Figure 4.17 (c) and is the total dose taken by line profile
through the inferior film strip shown in Figure 4.5
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Figure 4.17: Total dose from all treatment fields for (a) the superior detector strip location (b) the middle detector strip location and (c) the inferior detector strip location
as shown in Figure 4.3
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Figure 4.18: Variation of surface dose with cast thickness and incident angle. Dose is
normalised to 1 cGy per MU. Courtesy of Nicholas Hardcastle

4.3.5

Variation of Suface Dose with Cast Thickness and Incident Angle

Figure 4.18 illustrates the effect of varying cast thickness (with a corresponding variation in hole size) on surface dose for different angles of incidence. Under a gap in the
cast material the thinner and thicker cast material results in an approximately 35%
to 48% increase in surface dose compared to when Orfit was absent respectively. This
increases to approximately 51% and 60% at a 75◦ angle of beam incidence.

4.4. Discussion
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Discussion
Film Measurements

The Gafchromic film results show an increase in surface dose as a result of the bolus
effect of the cast material. A possible source of error in the film measurements arises
from the difficulty in affixing the film to the anthropomorphic phantom without the
presence of air gaps behind the film. This lack of ideal backscatter may result in
reported dose to the surface at the midline being less than expected. The presence
of Orfit stretch holes can be clearly seen on the ’EBT Film Orfit’ film strip in Figure
4.5 by the modulation in dose measured by the film. It can also be seen that lateral
scatter from the Orfit structure surrounding a stretch-hole contributes to the surface
dose in the uncovered area of skin. This is evidenced by the dose in a stretch-hole
being higher than when the Orfit is not present.
Currently it is not understood by what amount larger stretch-holes in the immobilization cast could reduce a larger portion of the breast surface dose to a level
approaching that of no immobilization cast levels while maintaining requisite physical
rigidity for immobilization. One of the advantages in using the film dosimeter was the
ability to obtain a 2D dose map. It was seen in the results that MOSkin point dose
measurements lay somewhere between the oscillations in the film measurements in the
entrance surface dose measurements.

4.4.2

Orfit immobilization Cast

It was observed during the experiments that the immobilization cast varied in thickness due to non-uniform stretching over the anthropomorphic phantom. This is an
unavoidable aspect of using the cast material. How this affected the results during
the anthropomorphic experiments (dose increase from the Orfit in a given region) is
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not known given the complexity of both the anthropomorphic phantom geometry and
the field arrangement. Note a simple retrospective study was performed with nominal
small and large orfit holes (see Figure 4.18) to observe the effect of Orfit thickness on
surface dose in simple geometry. This demonstrated a significant bolus effect from the
Orfit both under the material and under the stretch holes.
It was also observed that the Orfit was not in direct contact with the phantom
surface in every region. In particular, the Orfit did not sit perfectly at the midline. This
could possibly be the reason why the same cross-hatched patterning is not observed in
this region when using the 311◦ gantry angle. The elevation of the cast material from
the surface would allow greater scattering and dispersion of secondary photons and
electrons set in motion within the cast structure by the time it reached the phantom
surface.

4.4.3

MOSkin Measurements

Under calibration irradiation conditions at the surface, MOSkins measure dose at
70µm WED and EBT film at 153µm WED. In ideal, normally incident radiation the
MOSkins measure a lower dose than film as a result of the different WED. Surface
dose in breast radiotherapy is by contrast much more complicated. The placements of
MOSkins in this experiment experienced: highly oblique beam angles, multiple field
sizes, position variation within large fields, and varying backscatter conditions. All
MOSkins were placed face up on the phantom surface throughout measurements and
the measurement conditions varied from 0-360 degrees angle of incidence. That is, the
MOSkins were measuring both the contribution of entrance and exit dose to the total
surface dose. Keeping the MOSkins face up regardless of beam orientation results in a
water equivalent material thickness of 70µm above the measurement depth for either
build-up or build-down, depending on which beam angle is being used. It is therefore
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difficult to deduce precisely at what effective depth the MOSkins are measuring.
An additional complication arises when using the MOSkins to determine the increase in dose to the surface as a result of the cast material. This is because any one
MOSkin may be completely, partially, or not at all covered by the Orfit structure. The
effect of this on the dose measurement at the surface is likely to be similar to that
seen with the film results. In Figure 4(b) at 32.5 cm, a dose through corresponding to
an Orfit stretch-hole measured approximately 60cGy. Contrasting this to the adjacent
dose peak which measured approximately 80cGy, it can be appreciated that point dose
measurements could be misleading in determining the effect of the immobilization cast.
When inspecting the MOSkin placements under the cast material, it was noted that
some dosimeters were partially or fully obscured as the results suggest.

Chapter 5
Conclusion
The use of an immobilization cast caused significant increases in surface dose to the
breast phantom. Whether the extra skin reaction is worth incurring for the benefit
of: higher reproducibility, potentially lower heart and lung dose, and a reduction in
breast separation is a matter for further consideration by Radiation Oncologists.
Using film as a dosimeter allowed for greater spatial dose information than the
MOSkins but suffered in: the time between irradiation and read-out, and needing to
change films between fields to isolate their individual dose information. The MOSkins
provided on-line dose information which was reasonably consistent with film results.

5.1

Research Questions

1. Can surface dose prediction in the build-up region be improved in Pinnacle RTP
with the use of data from a Monte Carlo simulated linear accelerator to build
the beam model?
Pinnacle surface calculations were improved with the use of Monte Carlo data
for the perpendicular and sloping phantom geometries used. The limiting factor
for further improvement is likely the voxel resolution of the CT data set and
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dose grids. Concave and convex contours were not assessed.

2. What are the typical increases in skin dose in breast radiotherapy when using
an Orfit immobilisation cast?
The MOSkin dosimeters showed a maximum increase at 70µm water equivalent
depth of approximately 50%, 45% and 49% for the superior, middle and inferior detector strip respectively, relative to surface dose with no Orfit. EBT film
showed average in-field dose increases: (a) (34.5 ± 17.5)% in the superior film
strip, (b) (25 ± 18.3)% across the breast apex and (c) (17.6 ± 10.3)% inferior
to the breast.

3. What are the advantages and disadvantages of EBT film and MOSkin dosimeters
for in-vivo breast dose measurement?
The MOSkin has the advantage of being an online dosimeter with a measurement
depth of 70µm. EBT film provided a more informative dose map but was not
online and so intervention during delivery is not possible. The EBT used in this
study is no longer available but a new EBT2 film is being manufactured which
has a different construction and different WED which would require further
characterisation before use in similar applications.

5.2

Summary

Monte Carlo data can be used to improve the Pinnacle beam model in the build-up
region but gains are reduced by practical voxel constraints.
The benchmarking phantom measurements in this report renders them patient
ready for breast patient skin dose measurements.
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Immobilisation material does increase skin dose. While the typical extra dose
due to the cast has been quantified here, the skin reaction versus benefit from better
immobilisation remains an open question.

Chapter 6
Appendix
6.1

Monte Carlo Dose File Processing

The MATLAB code below was first written by Nicholas Hardcastle and designed to
read the 3ddose file output by the dosxyz monte carlo scoring code for 2mm cubed
voxels. It was further modified to be able to read dose from a phantom that had
scoring volumes to represent EBT film and MOSkins and the surface and at dmax. The
code was also used when benchmarking the Monte Carlo (Beamnrc) linear accelerator
against ion chamber data.

%% this will take a .3ddose file created in a dosxyz simulation and load it
%% into a 3D dose cube. This can then be manipulated as desired.

% Author: Nick Hardcastle
% Date Written: 22/3/08
% Last Update: 27/11/08 by Andrew Kelly

function [doseCube, doseError, dimX, dimY, dimZ, xBoundaries, yBoundaries, zBoundar
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%% This section loads the .3ddose file:

FPath = 'C:\Documents and Settings\Varian\Desktop\Andrew\';
%field = 7
%display('The field to be loaded is: ')
%disp(field)

[dFILENAME, dPATHNAME] = uigetfile([FPath '*.3ddose'], 'Open .3ddose file:');

filename=[dPATHNAME dFILENAME];

doseFile = fopen(filename);

display('File loaded')

%% This section loads the dimensions of the dose grid into a matrix. It
%% then loads the boundaries of the dose voxels into matricies.
display('Reading in cube dimensions...')
dim = fscanf(doseFile, '%f', 3);

dimX = dim(1,1);
display('x dimension: ')
disp(dimX)
dimY = dim(2,1);
display('y dimension: ')
disp(dimY)
dimZ = dim(3,1);
display('z dimension: ')
disp(dimZ)

display('...done')
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display('Computing voxel boundaries...')
xBoundaries = fscanf(doseFile, '%f', dimX+1);
yBoundaries = fscanf(doseFile, '%f', dimY+1);
zBoundaries = fscanf(doseFile, '%f', dimZ+1);
display('...done')

%% This section loads the dose values into a 3D matrix. It then loads the
%% corresponding errors into a 3D matrix.
doseCube = zeros(dimX,dimY,dimZ);

display('Reading in dose values...')
for i=1:dimX
doseCube(:,:,i) = fscanf(doseFile, '%f', [dimX,dimY]);
end
display('...done')

doseError = zeros(dimX,dimY,dimZ);

display('Reading in error values...')
for j=1:dimY
doseError(:,:,j) = fscanf(doseFile, '%f', [dimX,dimY]);
end
display('...done')

depth15mm=doseCube(:,:,8);
depth15mmX=depth15mm(:,125);
depth15mmY=depth15mm(125,:);

depth5cm=doseCube(:,:,26);
depth5cmX=depth5cm(:,125);
depth5cmY=depth5cm(125,:);
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depth10cm=doseCube(:,:,51);
depth10cmX=depth10cm(:,125);
depth10cmY=depth10cm(125,:);

depth15cm=doseCube(:,:,76);
depth15cmX=depth15cm(:,125);
depth15cmY=depth15cm(125,:);

depth20cm=doseCube(:,:,101);
depth20cmX=depth20cm(:,125);
depth20cmY=depth20cm(125,:);

depthsurf=doseCube(:,:,1);
depthsurfX=depthsurf(:,125);
depthsurfY=depthsurf(125,:);

depthMOS=doseCube(:,:,2);
depthMOSX=depthMOS(:,125);
depthMOSY=depthMOS(125,:);

depthFILMsurf=doseCube(:,:,4);
depthFILMsurfX=depthFILMsurf(:,125);
depthFILMsurfY=depthFILMsurf(125,:);

depthFILMdmax=doseCube(:,:,6);
depthFILMdmaxX=depthFILMdmax(:,125);
depthFILMdmaxY=depthFILMdmax(125,:);

depth15mmerror=doseError(:,:,8);
depth15mmXerror=depth15mmerror(:,125);
depth15mmYerror=depth15mmerror(125,:);
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depth5cmerror=doseError(:,:,26);
depth5cmXerror=depth5cmerror(:,125);
depth5cmYerror=depth5cmerror(125,:);

depth10cmerror=doseError(:,:,51);
depth10cmXerror=depth10cmerror(:,125);
depth10cmYerror=depth10cmerror(125,:);

depth15cmerror=doseError(:,:,76);
depth15cmXerror=depth15cmerror(:,125);
depth15cmYerror=depth15cmerror(125,:);

depth20cmerror=doseError(:,:,101);
depth20cmXerror=depth20cmerror(:,125);
depth20cmYerror=depth20cmerror(125,:);

depthsurferror=doseError(:,:,1);
depthsurfXerror=depthsurferror(:,125);
depthsurfYerror=depthsurferror(125,:);

depthMOSerror=doseError(:,:,2);
depthMOSXerror=depthMOSerror(:,125);
depthMOSYerror=depthMOSerror(125,:);

depthFILMsurferror=doseError(:,:,4);
depthFILMsurfXerror=depthFILMsurferror(:,125);
depthFILMsurfYerror=depthFILMsurferror(125,:);

depthFILMdmaxerror=doseError(:,:,6);
depthFILMdmaxXerror=depthFILMdmaxerror(:,125);
depthFILMdmaxYerror=depthFILMdmaxerror(125,:);
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%get central axis PDD data:
z = doseCube(125,125,:)
numElements = size(z)

clear i

for i=1:numElements(1,3)
caxPDD(i,1) = z(:,:,i);
end

zError = doseError(125,125,:)
numElementsError = size(zError)
clear i

for i=1:numElementsError(1,3)
caxErrorPDD(i,1) = zError(:,:,i);
end

%transposing the Y profiles
clear i
transposeA=size(depthsurfY)
for i=1:transposeA(1,2)
depthsurfYtrans(i,1)=depthsurfY(1,i);

end
clear i
transposeB=size(depthMOSY)
for i=1:transposeB(1,2)
depthMOSYtrans(i,1)=depthMOSY(1,i);

end
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clear i
transposeC=size(depthFILMsurfY)
for i=1:transposeC(1,2)
depthFILMsurfYtrans(i,1)=depthFILMsurfY(1,i);

end
clear i
transposeD=size(depthFILMdmaxY)
for i=1:transposeD(1,2)
depthFILMdmaxYtrans(i,1)=depthFILMdmaxY(1,i);

end
clear i
transposeE=size(depth15mmY)
for i=1:transposeE(1,2)
depth15mmYtrans(i,1)=depth15mmY(1,i);

end
clear i
transposeF=size(depth5cmY)
for i=1:transposeF(1,2)
depth5cmYtrans(i,1)=depth5cmY(1,i);

end
clear i
transposeG=size(depth10cmY)
for i=1:transposeG(1,2)
depth10cmYtrans(i,1)=depth10cmY(1,i);

end
clear i
transposeH=size(depth15cmY)
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for i=1:transposeH(1,2)
depth15cmYtrans(i,1)=depth15cmY(1,i);

end
clear i
transposeI=size(depth20cmY)
for i=1:transposeI(1,2)
depth20cmYtrans(i,1)=depth20cmY(1,i);

end
clear i
transposeJ=size(depthsurfYerror)
for i=1:transposeJ(1,2)
depthsurfYerrortrans(i,1)=depthsurfYerror(1,i);

end
clear i
transposeK=size(depthMOSYerror)
for i=1:transposeK(1,2)
depthMOSYerrortrans(i,1)=depthMOSYerror(1,i);

end
clear i
transposeL=size(depthFILMsurfYerror)
for i=1:transposeL(1,2)
depthFILMsurfYerrortrans(i,1)=depthFILMsurfYerror(1,i);

end
clear i
transposeM=size(depthFILMdmaxYerror)
for i=1:transposeM(1,2)
depthFILMdmaxYerrortrans(i,1)=depthFILMdmaxYerror(1,i);
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end
clear i
transposeN=size(depth15mmYerror)
for i=1:transposeN(1,2)
depth15mmYerrortrans(i,1)=depth15mmYerror(1,i);

end
clear i
transposeO=size(depth5cmYerror)
for i=1:transposeO(1,2)
depth5cmYerrortrans(i,1)=depth5cmYerror(1,i);

end
clear i
transposeP=size(depth10cmYerror)
for i=1:transposeP(1,2)
depth10cmYerrortrans(i,1)=depth10cmYerror(1,i);

end
clear i
transposeQ=size(depth15cmYerror)
for i=1:transposeQ(1,2)
depth15cmYerrortrans(i,1)=depth15cmYerror(1,i);

end
clear i
transposeR=size(depth20cmYerror)
for i=1:transposeR(1,2)
depth20cmYerrortrans(i,1)=depth20cmYerror(1,i);

end
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end
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Dose extraction from CERR

The Matlab code below can be used to extract any desired dose profiles from a dose
array that is calculated in Pinnacle once it is exported into CERR. The main working
part of the code was written by Nicholas Hardcastle. The code was modified by Andrew
Kelly to be able to extract data from the data sets as required for this thesis.

dose=planC{1,8}(1,14).doseArray;
p180deg10sqsurf=dose(3,:,36);
clear i
transpose=size(p180deg10sqsurf)
for i=1:transpose(1,2)
p180deg10sqsurftrans(i,1)=p180deg10sqsurf(1,i);
end
p180deg10sqmax=dose(10,:,36);
clear i
for i=1:transpose(1,2)
p180deg10sqmaxtrans(i,1)=p180deg10sqmax(1,i);
end
%clear dose
%clear p180deg10sqsurf p180deg10sqsurftrans p180deg10sqmax p180deg10sqmaxtrans
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